Hepsera
(Adefovir Dipivoxil)
Articles on Hepsera
Prescribing
Information
What
are Hepsera's Possible Side Effects?
Important
Safety Information about Hepsera
Is
There Resistance to Hepsera?

Articles on Hepsera (Adefovir Dipivoxil)
Entecavir
Beats Adefovir for Hepatitis
B Treatment
3-29-2011
Add-on
Hepsera Is More Effective and
Durable Than a Switch to Baraclude as Rescue Therapy for Epivir-resistant
Patients with Chronic Hepatitis B
11-09-2010
Adding
Adefovir Works Better than
Entecavir Monotherapy for Lamivudine-resistant Hepatitis B Patients
8-27-2010
Tenofovir
(Viread) Effective for Treatment of Chronic Hepatitis B Patients
with Suboptimal Response to Adefovir (Hepsera)
5-7-2010
Entecavir (Baraclude) Works Well
in Patients with Adefovir-resistant
Hepatitis B, but Lamivudine Resistance Compromises Efficacy
4/02/2010
Adding
Adefovir (Hepsera) to Lamivudine
(Epivir-HBV) Extends Biochemical Response, But May Cause Kidney
Problems
3/19/2010
Efficacy
and Safety of Entecavir Versus
Adefovir in Chronic Hepatitis B Patients with Evidence
of Hepatic Decompensation
11/03/09
Tenofovir
Disoproxil Fumarate for patients with chronic hepatitis B who have
previously failed Lamivudine and
Adefovir: effects of baseline sequence mutations on virological
response.
11/03/09
Entecavir (Baraclude)
Demonstrates Greater Antiviral Activity than Adefovir
(Hepsera) in Hepatitis B Patients with Decompensated
Liver Disease
11/03/09
Entecavir (ETV) Therapy in Chronic Hepatitis
B Patients Previously Treated with Adefovir
(ADV) with Incomplete Response On-Treatment or Relapse
Off-Treatment
6/05/09
Half
of HBeAg Negative Chronic Hepatitis B Patients Maintain Response
up to 5 Years after Stopping Long-term Adefovir (Hepsera)
5/05/09
Chronic
Hepatitis B Patients Who Had Incomplete Response or Relapse on Adefovir
(Hepsera) Respond Well to Entecavir (Baraclude)
5/01/09
Some
Individuals Harbor HBV with Adefovir (Hepsera) and Tenofovir
(Viread) Resistance Mutations before They Ever Receive Treatment
4/17/09
Two Year Tenofovir Disoproxil Fumarate (TDF) Treatment
and Adefovir Dipivoxil (ADV) Switch
Data in HBeAg-Positive Patients With Chronic Hepatitis B (Study
103)
3/27/09
Adefovir
(Hepsera) Prevents Post-transplant HBV Recurrence as
well as HBIG
1/27/2009
Higher
Dose of Adefovir (Hepsera) Are
Not Effective for Chronic Hepatitis B Patients with Lamivudine (Epivir)
Resistance
1/09/2009

What
are Hepsera's Possible Side Effects?
Hepsera®
(adefovir dipivoxil) was compared to a sugar pill (placebo) in clinical
trials. The most common side effects observed were weakness, headache,
stomach pain and nausea.
Hepsera also
can cause the following serious side effects (See Important Safety
Information): very serious hepatitis if you stop taking it, a severe
kidney problem called nephrotoxicity, lactic acidosis (buildup of
acid in the blood) and liver problems.
The most common
side effects in patients with liver transplants and chronic hepatitis
B were weakness, headache, stomach pain and itching. Some patients
with liver transplants also had changes in the way their kidneys
worked. If you notice any side effects while taking Hepsera, talk
to your healthcare provider about what to do.
Important
Safety Information
1. Some people who stop taking Hepsera get a very serious
hepatitis. This usually happens within 12 weeks after stopping.
You will need to have regular blood tests to check for liver function
and hepatitis B virus levels if you stop taking Hepsera.
2. Hepsera
may cause a severe kidney problem called nephrotoxicity. It
usually happens in people that already have a kidney problem, but
it can happen to anyone that uses Hepsera. You will need to have
regular blood tests to check for kidney function while you are taking
Hepsera.
3. Some
people who have taken medicines like Hepsera that are called nucleoside
or nucleotide analogs have developed a serious condition called
lactic acidosis (build up of an acid in the blood). Lactic acidosis
is a medical emergency and must be treated in the hospital. Call
your doctor right away if you get any of the following signs of
lactic acidosis:
You feel
very weak or tired.
You have unusual (not normal) muscle pain.
You have trouble breathing.
You have stomach pain with nausea and vomiting.
You feel cold, especially in your arms and legs.
You feel dizzy or lightheaded.
You have a fast or irregular heartbeat.
Some people
who have taken medicines like Hepsera have developed serious liver
problems called hepatotoxicity, with liver enlargement (hepatomegaly)
and fat in the liver (steatosis). Call your doctor right away
if you get any of the following signs of liver problems.
Your
skin or the white part of your eyes turns yellow (jaundice).
Your urine turns dark.
Your bowel movements (stools) turn light in color.
You don't feel like eating food for several days or longer.
You feel sick to your stomach (nausea).
You have lower stomach pain.
You may be
more likely to get lactic acidosis or serious liver problems if
you are very overweight (obese) or have been taking nucleoside
analog medicines [Atripla (efavirenz plus emtricitabine
plus tenofovir disoproxil fumarate), Combivir® (zidovudine
plus lamivudine), Emtriva® (emtricitabine), Epivir® Epivir-HBV®
(lamivudine), Epzicom (abacavir plus lamivudine), Hivid®
(zalcitabine), Retrovir® (zidovudine), Trizivir® (zidovudine
plus lamivudine plus abacavir), Truvada® (emtricitabine plus
tenofovir disoproxil), Videx® (didanosine), Viread® (tenofovir
disoproxil fumarate), Zerit® (stavudine) and Ziagen® (abacavir)]
for a long time.
4.
If you get or have HIV that isn't being treated with medicines,
Hepsera may increase the chances your HIV infection cannot be
helped with usual HIV medicines. This can happen if you get
or have HIV and don't know it, or if your HIV is not being treated
while you are taking Hepsera. You should get an HIV test before
you start taking Hepsera and any time after that when there's
a chance you were exposed to HIV.
Is
There Resistance to Hepsera?
Drug resistance
is a primary concern of infectious disease specialists around
the world. Any virus can develop drug resistance, and may even
develop resistance to more than one drug. Resistance occurs when
viruses acquire ways to survive the effects of the drugs that
were designed to weaken them. Resistance to antiviral drugs presents
an obstacle to providing effective long-term treatment of viral
diseases, such as chronic hepatitis B.
Hepsera®
was studied in clinical trials to find out whether or not resistance
would develop. Through 144 weeks (about 3 years), resistance mutations
were identified that may reduce the effectiveness of Hepsera.
After 3 years of continuous treatment, 4/100 patients developed
resistance to Hepsera in clinical trials.
In clinical
trials, Hepsera was found to work well in people who had hepatitis
B virus that was resistant to the currently approved chronic hepatitis
B treatment, lamivudine.
|